BTIG reiterates Buy rating on ORIC Pharmaceuticals, $26 price target
BTIG maintained a Buy rating on ORIC Pharmaceuticals with a $26 price target, suggesting a 188.9% upside from its Oct 27 close of $9. The firm cited strong early efficacy data for rinzimetostat and an attractive entry point ahead of the MEVPRO-1 readout.
How this was made

The 30-second read
Why it matters
The reiteration of a Buy rating with a substantially higher target may attract short-term buying interest.
Market read
Analyst upgrade provides a fresh catalyst for ORIC, potentially driving short-term price appreciation.
What to watch
Potential regulatory hurdles and competition in the mCRPC space could temper upside.
Background
BTIG's analyst note highlights early efficacy data for ORIC's rinzimetostat and sets a new price target.
Ticker impact
BTIG reiterated a Buy rating on ORIC Pharmaceuticals with a new $26 price target, implying a 188.9% upside.
likely upward pressure as the market absorbs the higher target
The rating change is new to the market and provides a concrete upside thesis, but no new operational data accompanies it.
Market effects
May boost sentiment in the biotech/oncology sector as peers see a higher valuation benchmark.
Limited to US biotech investors; no broader regional effect.
Minimal global impact beyond niche biotech investors.
Counterpoint
The price target may be overly optimistic given the early-stage data; investors could wait for more mature trial results.
Key entities
- companyORIC Pharmaceuticals
Biotech firm developing oncology therapies.
- analyst_firmBTIG
Equity research firm issuing the rating.
